MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Free Cash flow
-$31,247K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Stock-based compensation
    • Accounts payable
    • Non-cash lease expense
    • Others
Negative Cash Flow Breakdown
    • Proceeds from offering, net of i...
    • Proceeds from offering, net of i...
    • Accrued expenses
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-34,099
-32,588
-19,300
-25,579
Depreciation and amortization
34
33
42
40
Unrealized foreign currency gain
-
-
-
0
Stock-based compensation
6,782
4,466
1,308
3,614
Non-cash lease expense
209
151
341
48
Change in fair value of tranche rights
-
-
0
0
Fees expensed as part of january 2024 financing
-
-
0
0
Foreign currency loss
-
-
0
-
Other current assets and prepaid expenses
723
-5,214
3,116
-384
Accounts payable
1,769
1,091
2,164
-31
Accrued expenses
-4,526
4,208
-398
1,428
Other liabilities
-236
273
16
6
Operating lease liability
-208
-149
-338
-50
Net cash used in operating activities
-30,998
-17,301
-19,281
-20,140
Purchases of property and equipment
249
2
11
67
Net cash used in investing activities
-249
-2
-11
-67
Proceeds from january 2024 financing, net of issuance costs-January2024PIPETransaction
-
-
0
-
Proceeds from public offering of common stock through at the market offering, net of issuance costs
-
-
0
0
Proceeds from warrant exercises-Series BWarrants
0
1,377
-
-
Proceeds from offering, net of issuance costs-January2024PIPETransaction
-
-
-
0
Proceeds from issuance of private placement
0
187,263
-
-
Proceeds, issuance of shares, share-based payment arrangement, excluding option exercised
86
-
59
0
Proceeds from offering, net of issuance costs-May2025PIPETransaction
-60,661
-
-
0
Proceeds from offering, net of issuance costs-April2025PIPETransaction
-4,734
-
-
0
Proceeds from january 2024 financing, net of issuance costs-May2025PIPETransaction
-
-
60,661
-
Proceeds from the exercise of employee stock options
32
-
-
-
Proceeds from january 2024 financing, net of issuance costs-April2025PIPETransaction
-
-
4,734
-
Proceeds from warrant exercises-Pre Funded Warrants
0
2
-
-
Net cash provided by financing activities
118
188,642
59
0
Effect of exchange rate changes on cash and cash equivalents
-402
-193
-416
29
Net change in cash and cash equivalents
-31,531
171,146
-19,649
-20,178
Cash and cash equivalents, beginning of period
186,629
15,483
35,132
35,668
Cash and cash equivalents, end of period
155,098
186,629
15,483
35,132
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

something is missing$65,395K Proceeds, issuance ofshares, share-based...$86K (-30.08%↓ Y/Y)Proceeds from theexercise of employee...$32K Net cash provided byfinancing activities$118K (-99.82%↓ Y/Y)Canceled cashflow$65,395K Net change in cashand cash...-$31,531K (-260.53%↓ Y/Y)Canceled cashflow$118K Stock-based compensation$6,782K (72.09%↑ Y/Y)Accounts payable$1,769K (297.43%↑ Y/Y)Non-cash lease expense$209K (93.52%↑ Y/Y)Depreciation andamortization$34K (-60.47%↓ Y/Y)Proceeds from offering,net of issuance...-$60,661K (-200.00%↓ Y/Y)Proceeds from offering,net of issuance...-$4,734K (-200.00%↓ Y/Y)Net cash used inoperating activities-$30,998K (33.17%↑ Y/Y)Effect of exchange ratechanges on cash and cash...-$402K (-167.91%↓ Y/Y)Net cash used ininvesting activities-$249K (-200.00%↓ Y/Y)Canceled cashflow$8,794K Net loss-$34,099K (34.79%↑ Y/Y)Purchases of property andequipment$249K (200.00%↑ Y/Y)Accrued expenses-$4,526K (-231.30%↓ Y/Y)Other current assetsand prepaid...$723K (68.53%↑ Y/Y)Other liabilities-$236K (-2.16%↓ Y/Y)Operating lease liability-$208K (-76.27%↓ Y/Y)

IMMUNIC, INC. (IMUX)

IMMUNIC, INC. (IMUX)